The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis of COVID-19 in certain adults and paediatric individuals (12 years of age and older weighing at least 40 kg).
According to the FDA, the product is only authorised for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2. The authorisation also requires that individuals either have:
